These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 33324391)

  • 21. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer.
    Davies KD; Mahale S; Astling DP; Aisner DL; Le AT; Hinz TK; Vaishnavi A; Bunn PA; Heasley LE; Tan AC; Camidge DR; Varella-Garcia M; Doebele RC
    PLoS One; 2013; 8(12):e82236. PubMed ID: 24349229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activation of RAS family members confers resistance to ROS1 targeting drugs.
    Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
    Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
    Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
    Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
    Huang RSP; Haberberger J; Sokol E; Schrock AB; Danziger N; Madison R; Trabucco S; Jin D; Pavlick D; Ramanan V; Hole K; McGregor K; Venstrom J; Ross JS
    Int J Cancer; 2021 Apr; 148(7):1778-1788. PubMed ID: 33336398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD74-ROS1 L2026M mutant enhances autophagy through the MEK/ERK pathway to promote invasion, metastasis and crizotinib resistance in non-small cell lung cancer cells.
    Xu X; Li Y; Xu R; Meng Y; Li Z; Zuo D; Wu Y
    FEBS J; 2024 Mar; 291(6):1199-1219. PubMed ID: 38148635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.
    Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.
    Jóri B; Falk M; Hövel I; Weist P; Tiemann M; Heukamp LC; Griesinger F
    Curr Oncol; 2022 Sep; 29(9):6628-6634. PubMed ID: 36135089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
    Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas.
    Tsukita Y; Fujino N; Miyauchi E; Saito R; Fujishima F; Itakura K; Kyogoku Y; Okutomo K; Yamada M; Okazaki T; Sugiura H; Inoue A; Okada Y; Ichinose M
    Mol Cancer; 2019 Feb; 18(1):24. PubMed ID: 30744655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
    Roskoski R
    Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Zheng J; Cao H; Li Y; Rao C; Zhang T; Luo J; Lv D; Zhu Y; Zhou J; Zhou J
    Lung Cancer; 2020 Sep; 147():130-136. PubMed ID: 32702569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Construction of crizotinib resistant models with CD74-ROS1 D2033N and CD74-ROS1 S1986F point mutations to explore resistance mechanism and treatment strategy.
    Sun R; Meng Y; Xu R; Li Y; Xu X; Li Z; Zuo D
    Cell Signal; 2023 Jan; 101():110497. PubMed ID: 36265718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
    Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer.
    Chao YC; Lee KY; Wu SM; Kuo DY; Shueng PW; Lin CW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
    Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
    Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.